FBDIX : FRANKLIN BIOTECHNOLOGY DISCOVERY A

 
 
 
 
5

ZACKS RANK: 5 - STRONG SELL

Ticker: FBDIX
Manager: Evan McCulloch
Manager Since: 09/97
NAV (04/18/2014): 126.11
Objective: Equity - Sector Health
Peer: HL MG
Net Assets ($mil): 986.35
Inception: 09/15/1997
FBDIX : Description

The fund was incepted in September 1997 and is managed by Franklin Advisers. The objective of this fund is to seek capital appreciation. The fund invests at least 80% of its net assets in equity securities of biotechnology companies and discovery research firms worldwide, including therapeutics, drug delivery, gene therapy and other select medical companies. The fund invests a substantial portion of its assets in equity securities of smaller capitalization companies, which are generally companies with a market capitalization of less than $1.5 billion at the time of the fund's investment, and invests a small portion of its assets in private or illiquid securities, such as late stage venture capital financings. The fund offers dividends and capital gains annually. There is no guarantee that fund would regularly pay either income dividends or capital gains distributions.

FBDIX : Composition - 04/14
Stocks 91.29%
Foreign Stocks 4.47%
Cash 15.84%
Bonds 0.00%
Foreign Bonds 0.00%
Preferred 0.46%
Convertible 0.00%
Other -7.60%
Foreign Hedged 0.00%
Composition Horizontal Bar Chart
FBDIX : Style Analysis - 04/14
Large Growth 15.02%
Large Value 0.00%
Small Growth 3.66%
Small Value 0.00%
Foreign Stock 15.02%
Emerging Market 0.00%
Precious Metals 0.00%
Intermediate Bond 0.00%
High Yield Bond 0.00%
Foreign Bond 40.25%
Style Analysis Horizontal Bar Chart
FBDIX : Risk Analysis
Beta v. S&P 500 0.78
Beta v. EAFE 0.21
Beta v. Barclays Agg Bond 0.89
Alpha 3 Yr 18.89
Alpha 5 Yr 10.32
R-Sq 3 Yr 0.33
R-Sq 5 Yr 0.33
Std Dev 3 Yr 21.11
Std Dev 5 Yr 19.72
Sharpe 3 Yr 1.73
Sharpe 5 Yr 1.50
FBDIX : Fees
Expense Ratio 1.10
% Max Load 5.75
% Min Load 0.00
% Deferred Load NA
% Redemption NA
% Max 12 B1 Fee 0.29
% Max Mgt Fee 0.50
FBDIX : Purchase Choices:
Min Initial Investment 1000
Min Subsequent Investment 0
FBDIX : Returns Analysis - Annual

Line chart

  2004200520062007200820092010201120122013YTD
NAV ($) 53.6656.6459.4958.5452.3158.5068.6164.3683.18131.04126.11
Total Return (%) 11.955.555.03-1.59-10.6411.8317.288.3529.3468.646.71
Annual Dividend Yield (%) 0.000.000.000.000.000.000.000.660.070.000.00
Relative Performance
Rel Performance-S&P500(%) 10.826.63-107.64-70.92263.66-145.8822.1762.58133.54362.6049.15
Rel Performance-Obj.Ret.(%) 31.75-34.0912.97-104.62130.55-100.4492.566.09101.15223.34-1.00
Ret.Quintile vs Obj(1 is best) 25351512113
Turnover, Yields, and Gains
Fund Assets Net($mil) 599486473421298291333352469986986
Annual Turnover (%) 59.3934.3437.0042.0832.8445.5741.58235.1446.5433.640.00
Annual Dividend Paid ($) 0.000.000.000.000.000.000.000.510.060.000.00
Annual Capital Gains Paid($) 0.000.000.000.000.000.000.009.310.008.790.00
FBDIX : Returns Analysis - Trailing Total Return
  1 Month 3 Month 6 Month YTD 1 Year 3 Year 5 Year 10 Year 15 Year 20 Year
Total Return (through 04/14) -10.60% 6.71% 10.68% 6.71% 50.77% 33.83% 27.27% 12.85% 14.13% NA
Ret. Percentile vs. Obj. (1 is best) 89 51 89 51 2 7 28 20 1 NA
FBDIX : Stock Portfolio Snapshot - 04/14
Average Price/Earnings 43.11
Average Price/Book 5.32
Average EPS Growth 15.50
Average Market Value 37,357.00
FBDIX : Stock Sector Breakout - 04/14
Stock Sector Breakout
FBDIX : Top Holdings - 04/14
Name Weight Shares
GILEAD SCIENCES INC 9.39 1,645,300
BIOGEN IDEC INC 6.63 299,661
AMGEN INC 5.58 663,300
CELGENE CORP 5.48 509,700
INCYTE PHARMACEUTICALS INC 3.00 647,900
REGENERON PHARMACEUTICALS 4.04 197,909
ALEXION PHARMACEUTICALS INC 3.46 308,400
ILLUMINA INC 3.06 284,900
MEDIVATION INC 4.41 782,754